Orforglipron 6mg Tablets

Each order of AndroNorth Orforglipron 6mg contains one (1) satchet of sixty (60) tablets, each containing 6mg milligrams of highly pure Orforglipron.

Orforglipron tablets are an investigational, once-daily, orally administered small-molecule therapy being developed for the treatment of chronic metabolic diseases, including obesity and type 2 diabetes. Unlike injectable incretin therapies, orforglipron is designed as a non-peptide oral agent, offering the potential convenience of tablet dosing while targeting established metabolic pathways.

Orforglipron acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, a mechanism known to support glycemic control and body-weight reduction through effects on appetite regulation, gastric emptying, and insulin secretion. Its small-molecule structure is intended to provide consistent oral bioavailability without the need for injection or complex administration requirements.